Extent of surgery in clinically evident but operable MTC - When is central and/or lateral lympadenectomy indicated?

Thyroid Research

Volumn 6, Issue SUPPL.1, 2013, Pages

  Gimm, Oliver ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Centre of Surgery and Oncology   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875332434     PISSN: None     EISSN: 17566614     Source Type: Journal    
DOI: 10.1186/1756-6614-6-S1-S3     Document Type: Review

References (38)

1. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, Klar E, Surgery 2001 130 6 1044 1049 10.1067/msy.2001.118380a 11742336 (Pubitemid 34014572)
2. [The importance of lymph node dissection in medullary thyroid macrocarcinomas]. Hamy A, Raffaitin P, Floch I, Paineau J, Mirallie E, Visset J, Ann Chir 2003 128 7 447 451 10.1016/S0003-3944(03)00179-2 14559193 (Pubitemid 37163010)
3. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Machens A, Holzhausen HJ, Dralle H, Surgery 2006 139 1 28 32 10.1016/j.surg.2005.06.018 16364714 (Pubitemid 41814429)
4. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U, Dralle H, Cancer 2000 88 8 1909 1915 10.1002/(SICI)1097-0142(20000415)88:8<1909::AID-CNCR21>3.0.CO;2-A 10760769 (Pubitemid 30213002)
5. Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer. Kandil E, Gilson MM, Alabbas HH, Tufaro AP, Dackiw A, Tufano RP, Ann Surg Oncol 2011 18 4 1028 1034 10.1245/s10434-010-1363-y 21046269
6. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. Gimm O, Ukkat J, Dralle H, World J Surg 1998 22 6 562 567 discussion 567-568 10.1007/s002689900435 9597929 (Pubitemid 28215433)
7. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L, Cancer 1996 77 8 1556 1565 10.1002/(SICI)1097-0142(19960415)77:8<1556::AID- CNCR20>3.0.CO;2-Y 8608543 (Pubitemid 26105394)
8. [Prognostic factors of survival without clinical recurrences in medullary thyroid carcinoma: apropos of 52 operated cases]. Raffaitin P, Hamy A, Mirallie E, Meurette G, Duplessis R, Lemeunier P, Murat A, Le Bodic M, Le Neel JC, Paineau J, et al. Ann Endocrinol (Paris) 1999 60 6 435 442 10617796 (Pubitemid 30035594)
9. Long-term prognosis of medullary thyroid carcinoma. Rendl G, Manzl M, Hitzl W, Sungler P, Pirich C, Clin Endocrinol (Oxf) 2008 69 3 497 505 10.1111/j.1365-2265.2008.03229.x 18331612
10. Complications of neck dissection for thyroid cancer. Cheah WK, Arici C, Ituarte PH, Siperstein AE, Duh QY, Clark OH, World J Surg 2002 26 8 1013 1016 10.1007/s00268-002-6670-4 12045861 (Pubitemid 36920301)
11. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, et al. Thyroid 2009 19 6 565 612 10.1089/thy.2008.0403 19469690
12. Prediction of lateral lymph node metastases in medullary thyroid cancer. Machens A, Hauptmann S, Dralle H, Br J Surg 2008 95 5 586 591 10.1002/bjs.6075 18300267
13. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E, Geerlings H, Pichlmayr R, Surg Today 1994 24 2 112 121 10.1007/BF02473391 8054788 (Pubitemid 24081294)
14. Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Gimm O, Dralle H, Surgery 1997 122 6 1124 1130 discussion 1130-1121 10.1016/S0039-6060(97)90217-8 9426428 (Pubitemid 28016681)
15. Improved results of cervical reoperation for medullary thyroid carcinoma. Moley JF, Dilley WG, DeBenedetti MK, Ann Surg 1997 225 6 734 740 discussion 740-733 10.1097/00000658-199706000-00011 9230814 (Pubitemid 27310222)
16. Surgical strategy for the treatment of medullary thyroid carcinoma. Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI, Sellin RV, Friend KE, Burgess MA, Cote GJ, Gagel RF, et al. Ann Surg 1999 230 5 697 707 10.1097/00000658-199911000-00013 10561095 (Pubitemid 30191833)
17. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. Dralle H, Gimm O, Simon D, Frank-Raue K, Gortz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R, et al. World J Surg 1998 22 7 744 750 discussion 750-741 10.1007/s002689900463 9606292 (Pubitemid 28277872)
18. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Machens A, Lorenz K, Dralle H, Ann Surg 2009 250 2 305 310 10.1097/SLA.0b013e3181ae333f 19638924
19. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, J Clin Endocrinol Metab 2005 90 11 6077 6084 10.1210/jc.2005-0044 16091497 (Pubitemid 41606528)
20. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. Machens A, Dralle H, J Clin Endocrinol Metab 2010 95 6 2655 2663 10.1210/jc.2009-2368 20339026
21. Pattern of nodal metastasis for primary and reoperative thyroid cancer. Machens A, Hinze R, Thomusch O, Dralle H, World J Surg 2002 26 1 22 28 Epub 2001 Nov 2022 10.1007/s00268-001-0176-3 11898029 (Pubitemid 36918813)
22. Medullary thyroid microcarcinoma recommendations for treatment-a single-center experience. Scheuba C, Kaserer K, Bieglmayer C, Asari R, Riss P, Drosten R, Niederle B, Surgery 2007 142 6 1003 1010 discussion 1010 e1001-1003 10.1016/j.surg.2007.09.016 18063088 (Pubitemid 350184107)
23. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. Ahn JE, Lee JH, Yi JS, Shong YK, Hong SJ, Lee DH, Choi CG, Kim SJ, World J Surg 2008 32 7 1552 1558 10.1007/s00268-008-9588-7 18408961
24. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. Szakall Jnr. S, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, Agoston P, Tron L, J Nucl Med 2002 43 1 66 71 11801705 (Pubitemid 34101190)
25. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Czepczynski R, Parisella MG, Kosowicz J, Mikolajczak R, Ziemnicka K, Gryczynska M, Sowinski J, Signore A, Eur J Nucl Med Mol Imaging 2007 34 10 1635 1645 10.1007/s00259-007-0479-1 17530247 (Pubitemid 47476927)
26. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma. Mucha SA, Kunert-Radek J, Pomorski L, Endokrynol Pol 2006 57 4 452 455 17006852
27. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A, Eur J Nucl Med 2000 27 5 490 496 10.1007/s002590050533 10853802 (Pubitemid 30262612)
28. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid. Krausz Y, Rosler A, Guttmann H, Ish-Shalom S, Shibley N, Chisin R, Glaser B, Clin Nucl Med 1999 24 4 256 260 10.1097/00003072-199904000-00008 10466522 (Pubitemid 29156338)
29. Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery. Schott M, Willenberg HS, Sagert C, Nguyen TB, Schinner S, Cohnen M, Cupisti V, Eisenberger CF, Knoefel WT, Scherbaum WA, Clin Endocrinol (Oxf) 2007 66 3 405 409 10.1111/j.1365-2265.2007.02747.x 17302876 (Pubitemid 46239301)
30. Biological relevance of medullary thyroid microcarcinoma. Machens A, Dralle H, J Clin Endocrinol Metab 2012 97 5 1547 1553 10.1210/jc.2011-2534 22399508
31. Medullary thyroid microcarcinoma: a population-level analysis of 310 patients. Kazaure HS, Roman SA, Sosa JA, Cancer 2012 118 3 620 627 10.1002/cncr.26283 21717441
32. Skip metastases in thyroid cancer leaping the central lymph node compartment. Machens A, Holzhausen HJ, Dralle H, Arch Surg 2004 139 1 43 45 10.1001/archsurg.139.1.43 14718274 (Pubitemid 38049617)
33. Skip metastases in medullary thyroid carcinoma: a single-center experience. Tavares MR, Michaluart P Jr., Montenegro F, Arap S, Sodre M, Takeda F, Brandao L, Toledo S, Ferraz A, Surg Today 2008 38 6 499 504 10.1007/s00595-007-3664-8 18516528 (Pubitemid 351758632)
34. The value of intraoperative pentagastrin testing in medullary thyroid cancer. Scheuba C, Bieglmayer C, Asari R, Kaczirek K, Izay B, Kaserer K, Niederle B, Surgery 2007 141 2 166 171 discussion 171-162 10.1016/j.surg.2006. 12.006 17263971 (Pubitemid 46149883)
35. Early malignant progression of hereditary medullary thyroid cancer. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, et al. N Engl J Med 2003 349 16 1517 1525 10.1056/NEJMoa012915 14561794 (Pubitemid 37255037)
36. Medullary Thyroid Cancer: It is a pain in the neck? Guerrero MA, Lindsay S, Suh I, Vriens MR, Khanafshar E, Shen WT, Gosnell J, Kebebew E, Duh QY, Clark OH, J Cancer 2011 2 200 205 21509150
37. Desmoplastic stromal reaction in medullary thyroid cancer-an intraoperative "marker" for lymph node metastases. Scheuba C, Kaserer K, Kaczirek K, Asari R, Niederle B, World J Surg 2006 30 5 853 859 10.1007/s00268-005-0391-4 16680600 (Pubitemid 43724117)
38. Desmoplasia in medullary thyroid carcinoma: a reliable indicator of metastatic potential. Koperek O, Scheuba C, Cherenko M, Neuhold N, De Micco C, Schmid KW, Niederle B, Kaserer K, Histopathology 2008 52 5 623 630 10.1111/j.1365-2559.2008.03002.x 18370959 (Pubitemid 351442672)